Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05164172 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Study acronym: REJOIN
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites revised (70)v33 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 69 to 70v32
  3. Study sites: 68 to 69v31
  4. Study sites: 67 to 68v30
  5. Study sites: 66 to 67v29
Show 27 earlier versionsHide 27 earlier versions
  1. Study sites: 64 to 66v28
  2. Study sites: 61 to 64v27
  3. Primary completion date: Sep 1, 2025 to Apr 30, 2028 Study sites: 58 to 61 · Completion date: Mar 1, 2026 to Apr 30, 2028v26 Show 2 more changesShow less
    • Study sites: 58 to 61
    • Completion date: Mar 1, 2026 to Apr 30, 2028
  4. Study sites: 56 to 58v25
  5. Study sites: 57 to 56v24
  6. Study sites: 54 to 57v23
  7. Study sites: 52 to 54v22
  8. Study sites: 51 to 52v21
  9. Study sites: 50 to 51v20
  10. Study sites: 49 to 50v19
  11. Study sites: 47 to 49v18
  12. Study sites: 44 to 47v17
  13. Study sites: 43 to 44v16
  14. Study sites: 40 to 43v15
  15. Study sites: 37 to 40v14
  16. Study sites: 36 to 37v13
  17. Study sites: 34 to 36v12
  18. Study sites: 32 to 34v11
  19. Study sites: 27 to 32v10
  20. Enrollment target: 610 to 600 Study sites: 13 to 27 · Secondary endpoints: 7 to 4v9 Show 2 more changesShow less
    • Study sites: 13 to 27
    • Secondary endpoints: 7 to 4

    See this version in full on ClinicalTrials.gov ↗

  21. Study sites: 10 to 13v8
  22. Study sites: 8 to 10v7
  23. Study sites: 6 to 8v6
  24. Study sites: 5 to 6v5
  25. Study sites: 4 to 5v4
  26. Study sites: 2 to 4v3
  27. Study sites: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
H. Lundbeck A/S
20 trials monitored
See 1 trial at risk
Migraine
467 trials monitored
See 24 trials at risk
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Trial Details
NCT Number NCT05164172
Lead Sponsor H. Lundbeck A/S
Conditions Migraine
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov